Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform Expectations

Fiona Craig

Mon, April 27, 2026 astatine 10:08 AM CDT 2 min read

Fulcrum Therapeutics Inc. (NASDAQ:FULC) moved higher successful pre-market trading connected Monday aft reporting first-quarter results that topped expert expectations.

The clinical-stage biopharmaceutical steadfast posted a nonaccomplishment of $0.25 per stock for the quarter, coming successful up of forecasts calling for a $0.30 per stock loss. Net nonaccomplishment totaled $18.9 cardinal for the 3 months ended March 31, 2026, compared with $17.7 cardinal successful the aforesaid play a twelvemonth earlier. Shares gained 2.81% successful pre-market enactment pursuing the announcement.

During the quarter, the institution highlighted encouraging objective findings for pociredir, noting beardown induction of fetal hemoglobin on with improvements successful cardinal indicators of hemolysis and anemia. Fulcrum said it is targeting the motorboat of a imaginable registration-enabling proceedings successful the 2nd fractional of 2026, taxable to feedback from the FDA.

“The spot of the objective information presented successful the archetypal 4th further reenforce our condemnation successful pociredir’s imaginable to code the underlying biology of sickle compartment disease,” said Alex C. Sapir, Fulcrum’s President and Chief Executive Officer. “With a beardown equilibrium expanse extending our currency runway into 2029, we are good positioned to beforehand pociredir done the adjacent signifier of objective development.”

Research and improvement spending roseate twelvemonth implicit twelvemonth to $14.1 cardinal from $13.4 million, chiefly reflecting higher worker compensation. General and administrative expenses besides increased, reaching $8.1 cardinal compared to $7.0 million, driven by higher personnel-related and nonrecreational services costs.

Fulcrum ended the 4th with $333.3 cardinal successful cash, currency equivalents, and marketable securities, down from $352.3 cardinal astatine the extremity of 2025. The institution expects its existing superior resources to enactment operations done 2029.

Additionally, Fulcrum announced that it has dosed the archetypal subordinate successful an open-label, semipermanent survey designed to measure the information and durability of pociredir. The institution besides disclosed that Chief Financial Officer Alan Musso intends to discontinue aboriginal this twelvemonth and volition enactment connected until a successor is appointed.

Fulcrum Therapeutics Inc. is simply a clinical-stage biopharmaceutical institution focused connected processing therapies that people the basal causes of genetically defined diseases, peculiarly successful areas with important unmet aesculapian need.

Fulcrum Therapeutics banal price